UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Moderna, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

60770K 10 7

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Flagship VentureLabs IV, LLC

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  0

  6     

  SHARED VOTING POWER

 

  11,460,435

  7     

  SOLE DISPOSITIVE POWER

 

  0

  8     

  SHARED DISPOSITIVE POWER

 

  11,460,435

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  11,460,435

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  3.48%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  OO

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Flagship Ventures Fund IV, LP

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  0

  6     

  SHARED VOTING POWER

 

  49,334,859

  7     

  SOLE DISPOSITIVE POWER

 

  0

  8     

  SHARED DISPOSITIVE POWER

 

  49,334,859

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  49,334,859

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  15.00%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Flagship Ventures Fund IV-Rx, L.P.

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  0

  6     

  SHARED VOTING POWER

 

  9,468,596

  7     

  SOLE DISPOSITIVE POWER

 

  0

  8     

  SHARED DISPOSITIVE POWER

 

  9,468,596

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  9,468,596

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.88%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Flagship Ventures Fund IV General Partner LLC

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  6     

  SHARED VOTING POWER

 

  58,803,455

  7     

  SOLE DISPOSITIVE POWER

 

  0

  8     

  SHARED DISPOSITIVE POWER

 

  58,803,455

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  58,803,455

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  17.88%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  OO

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Flagship Pioneering, Inc.

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  37,040

  6     

  SHARED VOTING POWER

 

  0

  7     

  SOLE DISPOSITIVE POWER

 

  37,040

  8     

  SHARED DISPOSITIVE POWER

 

  0

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  37,040

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  .01%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  CO

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Noubar B. Afeyan, Ph.D.

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  82,508

  6     

  SHARED VOTING POWER

 

  58,840,495

  7     

  SOLE DISPOSITIVE POWER

 

  82,508

  8     

  SHARED DISPOSITIVE POWER

 

  58,840,495

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  58,923,003

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  17.90%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN

  1       

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Edwin M. Kania, Jr.

  2      

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒

 

  3      

  SEC USE ONLY

 

  4      

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

    5     

  SOLE VOTING POWER

 

  0

  6     

  SHARED VOTING POWER

 

  58,803,455

  7     

  SOLE DISPOSITIVE POWER

 

  0

  8     

  SHARED DISPOSITIVE POWER

 

  58,803,455

  9      

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  58,803,455

10      

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11      

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  17.91%

12      

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN

Item 1(a).

Name of Issuer :

Moderna, Inc. (the “Issuer”)

 

Item 1(b).

Address of Issuer’s Principal Executive Offices :

200 Technology Square

Cambridge, MA 02139

 

Item 2(a).

Names of Persons Filing :

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

Flagship VentureLabs IV, LLC (“VentureLabs IV”)

Flagship Ventures Fund IV, L.P. (“Flagship IV Fund”)

Flagship Ventures Fund IV-Rx, L.P. (“Flagship IV-Rx Fund”)

Flagship Ventures Fund IV General Partner LLC (“Flagship IV GP”)

Flagship Pioneering, Inc. (“Flagship Pioneering”)

Noubar B. Afeyan, Ph.D. (“Dr. Afeyan”)

Edwin M. Kania, Jr. (“Mr. Kania)

 

Item 2(b).

Address of Principal Business Office or, if None, Residence :

The address of the principal business office of each of the Reporting Persons is:

c/o Flagship Pioneering Inc.

55 Cambridge Parkway, Suite 800E

Cambridge, Massachusetts 02142

 

Item 2(c).

Citizenship :

VentureLabs IV                      Delaware

Flagship IV Fund                    Delaware

Flagship IV-Rx Fund              Delaware

Flagship IV GP                       Delaware

Flagship Pioneering                Delaware

Dr. Afeyan                              United States of America

Mr. Kania                               United States of America

 

Item 2(d).

Title of Class  of Securities :

Common Stock, $0.0001 par value per share (“Common Stock”).

 

Item 2(e).

CUSIP Number :

60770K 10 7

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership .

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 328,948,088 shares of outstanding Common Stock, as reported in the Issuer’s prospectus filed on December 7, 2018.

Flagship IV Fund is the manager of VentureLabs IV and, as such, may be deemed to beneficially own the shares held by VentureLabs.

Flagship IV GP is the general partner of each of Flagship IV Fund and Flagship IV-Rx Fund, and, as such, may be deemed to beneficially own the shares beneficially owned by Flagship IV Fund and Flagship IV-Rx Fund.

Dr. Afeyan and Mr. Kania are the managers of Flagship IV GP and, as such, may be deemed to beneficially own shares beneficially owned by Flagship IV GP. While Mr. Kania is retired from Flagship Pioneering he continues to serve as a manager of Flagship IV GP.

Dr. Afeyan is the Chief Executive Officer and a stockholder of Flagship Pioneering and, as such, may be deemed to beneficially own shares beneficially owned by Flagship Pioneering.

Each of the Reporting Persons expressly disclaims beneficial ownership of the shares reported in this Schedule 13G except to the extent of its or his pecuniary interest in such shares.

 

Item 5.

Ownership of Five Percent or Less of a Class .

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person .

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person .

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group .

Not applicable.

 

Item 9.

Notice of Dissolution of Group .

Not applicable.

 

Item 10.

Certification .

Not applicable.

Material Filed as Exhibits .

Exhibit 1 – Agreement regarding filing of joint Schedule 13G.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 11, 2019

 

FLAGSHIP VENTURES FUND IV, L.P.  
By:   Flagship Ventures Fund IV General Partner LLC  
  General Partner  
  By:  

/s/ Noubar B. Afeyan, Ph.D.

 
    Noubar B. Afeyan, Ph.D.  
    Manager  
FLAGSHIP VENTURES FUND IV-Rx, L.P.  
By:   Flagship Ventures Fund IV General Partner LLC  
  General Partner  
  By:  

/s/ Noubar B. Afeyan, Ph.D.

 
    Noubar B. Afeyan, Ph.D.  
    Manager  
FLAGSHIP PIONEERING, INC.  
  By:  

/s/ Noubar B. Afeyan, Ph.D.

 
    Noubar B. Afeyan, Ph.D.  
    Manager  
FLAGSHIP VENTURELABS IV, LLC  
By:   Flagship Ventures Fund IV, L.P.  
  Manager  
  By: Flagship Ventures Fund IV General Partner LLC  
  General Partner  
  By:  

/s/ Noubar B. Afeyan, Ph.D.

 
    Noubar B. Afeyan, Ph.D.  
    Manager  
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC  
  By:  

/s/ Noubar B. Afeyan, Ph.D.

 
    Noubar B. Afeyan, Ph.D.  
    Manager  

/s/ Noubar B. Afeyan, Ph.D.

Noubar B. Afeyan, Ph.D.

/s/ Edwin M. Kania, Jr.

Edwin M. Kania, Jr.

EXHIBIT 1

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 11, 2019

 

FLAGSHIP VENTURES FUND IV, L.P.
By:   Flagship Ventures Fund IV General Partner LLC
  General Partner
  By:  

/s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURES FUND IV-Rx, L.P.
By:   Flagship Ventures Fund IV General Partner LLC
  General Partner
  By:   /s/ Noubar B. Afeyan, Ph.D.
    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP PIONEERING, INC.
  By:   /s/ Noubar B. Afeyan, Ph.D.
    Noubar B. Afeyan, Ph.D.
    Manager
FLAGSHIP VENTURELABS IV, LLC
By:   Flagship Ventures Fund IV, L.P.
  Manager
  By:  

Flagship Ventures Fund IV General Partner LLC

General Partner

  By:  

/s/ Noubar B. Afeyan, Ph.D.

   

Noubar B. Afeyan, Ph.D.

Manager

FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
         By:  

/s/ Noubar B. Afeyan, Ph.D.

      Noubar B. Afeyan, Ph.D.
      Manager

/s/ Noubar B. Afeyan, Ph.D.

Noubar B. Afeyan, Ph.D.

/s/ Edwin M. Kania, Jr.

Edwin M. Kania, Jr.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Moderna Charts.